Molecular mechanisms of lower-grade (II–III) diffuse gliomas (LGG) are still poorly understood, mainly because of their heterogeneity. They split into astrocytoma- (IDH-A) and oligodendroglioma-like (IDH-O) tumors both carrying mutations(s) at the isocitrate dehydrogenase (IDH) gene and into IDH wild type (IDH-wt) gliomas of glioblastoma resemblance. We generated detailed maps of the transcriptomes and DNA methylomes, revealing that cell functions divided into three major archetypic hallmarks: (i) increased proliferation in IDH-wt and, to a lesser degree, IDH-O; (ii) increased inflammation in IDH-A and IDH-wt; and (iii) the loss of synaptic transmission in all subtypes. Immunogenic properties of IDH-A are diverse, partly resembling signatur...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Aims: Changes in metabolism are known to contribute to tumour phenotypes. If and how metabolic alter...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Molecular mechanisms of lower-grade (II–III) diffuse gliomas (LGG) are still poorly understood, main...
Abstract Background Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tu...
Background: Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, ma...
BACKGROUND Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, ma...
BACKGROUND Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, ma...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Abstract Glioblastoma (GBM) is the most common malignant primary central nervous system (CNS) neopla...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Aims: Changes in metabolism are known to contribute to tumour phenotypes. If and how metabolic alter...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Molecular mechanisms of lower-grade (II–III) diffuse gliomas (LGG) are still poorly understood, main...
Abstract Background Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tu...
Background: Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, ma...
BACKGROUND Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, ma...
BACKGROUND Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, ma...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Abstract Glioblastoma (GBM) is the most common malignant primary central nervous system (CNS) neopla...
Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma d...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Aims: Changes in metabolism are known to contribute to tumour phenotypes. If and how metabolic alter...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...